HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab-Reference-Cited by-同舟云学术

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Published:2011-05-10 Issue:15 Volume:17 Page:5132-5139
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Modi Shanu,Stopeck Alison,Linden Hannah,Solit David,Chandarlapaty Sarat,Rosen Neal,D'Andrea Gabriella,Dickler Maura,Moynahan Mary E.,Sugarman Steven,Ma Weining,Patil Sujata,Norton Larry,Hannah Alison L.,Hudis Clifford

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 366 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antagonistic interaction of HSP90 inhibitor XL-888 and 5-FU combination treatment in breast cancer cells;International Advanced Researches and Engineering Journal;2024-08-07

2. Towards Healthy Longevity: Comprehensive Insights from Molecular Targets and Biomarkers to Biological Clocks;International Journal of Molecular Sciences;2024-06-20

3. Mechanistic study of pre-eclampsia and macrophage-associated molecular networks: bioinformatics insights from multiple datasets;Frontiers in Genetics;2024-05-23

4. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer;Molecular Cancer;2024-05-07

5. Prospects and challenges of noncoding-RNA-mediated inhibition of heat shock protein 90 for cancer therapy;Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms;2024-03